Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

uniQure NV a un objectif de cours consensus de $58.76, basé sur les évaluations des 18 analystes. Le plus élevé est de $95 attribué par Guggenheim le septembre 25, 2025, et le plus bas est de $27 attribué par Chardan Capital le juin 22, 2023. Les 3 dernières évaluations d'analystes ont été publiées par Goldman Sachs, RBC Capital et HC Wainwright & Co. le novembre 4, 2025. Avec un objectif de cours moyen de $51 entre Goldman Sachs, RBC Capital et HC Wainwright & Co., il y a une variation implicite de 93.33% upside pour uniQure NV à partir de ces dernières évaluations d'analystes.
1calculé à partir des notes des analystes
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/04/2025 | 44.05% | Goldman Sachs | $56 → $38 | Maintains | Neutral | |||
11/04/2025 | 70.58% | RBC Capital | $65 → $45 | Maintains | Outperform | |||
11/04/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
11/04/2025 | 165.35% | HC Wainwright & Co. | $110 → $70 | Maintains | Buy | |||
11/03/2025 | 100.91% | Chardan Capital | $76 → $53 | Maintains | Buy | |||
10/06/2025 | 316.98% | HC Wainwright & Co. | $70 → $110 | Maintains | Buy | |||
10/02/2025 | 203.26% | Wells Fargo | $65 → $80 | Maintains | Overweight | |||
09/25/2025 | 112.28% | Goldman Sachs | $13 → $56 | Maintains | Neutral | |||
09/25/2025 | 127.45% | Mizuho | $30 → $60 | Maintains | Outperform | |||
09/25/2025 | 146.4% | Wells Fargo | $30 → $65 | Maintains | Overweight | |||
09/25/2025 | 260.12% | Guggenheim | $28 → $95 | Maintains | Buy | |||
09/25/2025 | 203.26% | Cantor Fitzgerald | $47 → $80 | Maintains | Overweight | |||
09/25/2025 | 188.1% | Chardan Capital | $35 → $76 | Maintains | Buy | |||
09/24/2025 | 146.4% | Stifel | $30 → $65 | Maintains | Buy | |||
09/24/2025 | 157.77% | Leerink Partners | $48 → $68 | Maintains | Outperform | |||
09/24/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
09/08/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
09/08/2025 | 32.68% | Chardan Capital | $35 → $35 | Maintains | Buy | |||
09/05/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
08/29/2025 | 32.68% | Chardan Capital | $35 → $35 | Maintains | Buy | |||
07/29/2025 | 32.68% | Chardan Capital | $38 → $35 | Maintains | Buy | |||
05/30/2025 | 44.05% | Chardan Capital | $38 → $38 | Maintains | Buy | |||
05/29/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
05/12/2025 | 6.14% | Guggenheim | $28 → $28 | Reiterates | Buy → Buy | |||
05/12/2025 | 44.05% | Chardan Capital | $38 → $38 | Maintains | Buy | |||
05/06/2025 | 44.05% | Chardan Capital | $38 → $38 | Maintains | Buy | |||
04/21/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
04/01/2025 | 44.05% | Chardan Capital | $27 → $38 | Maintains | Buy | |||
03/04/2025 | 165.35% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
02/28/2025 | 13.72% | Wells Fargo | $35 → $30 | Maintains | Equal-Weight | |||
01/27/2025 | 165.35% | HC Wainwright & Co. | $25 → $70 | Maintains | Buy | |||
01/21/2025 | -9.02% | RBC Capital | $24 → $24 | Reiterates | Outperform → Outperform | |||
12/19/2024 | -24.18% | Mizuho | $7 → $20 | Maintains | Neutral | |||
12/16/2024 | 21.3% | Stifel | $12 → $32 | Maintains | Buy | |||
12/12/2024 | -24.18% | Goldman Sachs | $9 → $20 | Maintains | Neutral | |||
12/11/2024 | 66.79% | Leerink Partners | — | $26 → $44 | Maintains | Outperform | ||
12/11/2024 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
12/11/2024 | -24.18% | RBC Capital | $14 → $20 | Maintains | Outperform | |||
12/10/2024 | -5.23% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy | |||
12/10/2024 | 97.12% | Raymond James | $20 → $52 | Upgrade | Outperform → Strong Buy | |||
12/10/2024 | 119.86% | Cantor Fitzgerald | $28 → $58 | Maintains | Overweight | |||
11/06/2024 | -5.23% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy | |||
11/06/2024 | -65.88% | Goldman Sachs | $10 → $9 | Maintains | Neutral | |||
11/06/2024 | -46.93% | RBC Capital | $16 → $14 | Maintains | Outperform | |||
11/06/2024 | 6.14% | Cantor Fitzgerald | $28 → $28 | Reiterates | Overweight → Overweight | |||
10/10/2024 | -24.18% | Raymond James | → $20 | Reinstates | → Outperform | |||
09/20/2024 | 6.14% | Cantor Fitzgerald | $28 → $28 | Reiterates | Overweight → Overweight | |||
08/20/2024 | -5.23% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy | |||
08/02/2024 | -62.09% | Goldman Sachs | $6 → $10 | Maintains | Neutral | |||
07/16/2024 | -9.02% | Cantor Fitzgerald | $24 → $24 | Reiterates | Overweight → Overweight | |||
07/09/2024 | -5.23% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy | |||
05/08/2024 | -5.23% | HC Wainwright & Co. | $25 → $25 | Reiterates | Buy → Buy | |||
05/08/2024 | -77.26% | Mizuho | $7 → $6 | Maintains | Neutral | |||
03/04/2024 | -73.46% | Mizuho | $10 → $7 | Maintains | Neutral | |||
03/01/2024 | -5.23% | HC Wainwright & Co. | $30 → $25 | Maintains | Buy | |||
02/29/2024 | -69.67% | Goldman Sachs | $63 → $8 | Downgrade | Buy → Neutral | |||
01/19/2024 | 13.72% | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
01/16/2024 | 6.14% | RBC Capital | $28 → $28 | Reiterates | Outperform → Outperform | |||
12/20/2023 | -20.39% | Cantor Fitzgerald | $21 → $21 | Reiterates | Overweight → Overweight | |||
12/19/2023 | -62.09% | Mizuho | → $10 | Downgrade | Buy → Neutral | |||
11/08/2023 | 138.82% | Goldman Sachs | $56 → $63 | Maintains | Buy | |||
08/02/2023 | 13.72% | HC Wainwright & Co. | $90 → $30 | Maintains | Buy | |||
08/02/2023 | 59.21% | RBC Capital | $47 → $42 | Maintains | Outperform | |||
08/02/2023 | 89.54% | Raymond James | $56 → $50 | Maintains | Outperform | |||
06/22/2023 | 2.35% | Chardan Capital | $45 → $27 | Maintains | Buy | |||
06/21/2023 | 241.17% | HC Wainwright & Co. | → $90 | Reiterates | Buy → Buy | |||
05/19/2023 | 59.21% | UBS | $45 → $42 | Maintains | Buy | |||
05/16/2023 | 70.58% | Chardan Capital | $56 → $45 | Maintains | Buy | |||
05/16/2023 | 112.28% | Raymond James | $58 → $56 | Maintains | Outperform | |||
05/11/2023 | 108.49% | Truist Securities | $65 → $55 | Maintains | Buy | |||
05/10/2023 | 100.91% | RBC Capital | → $53 | Reiterates | → Outperform | |||
03/07/2023 | 241.17% | HC Wainwright & Co. | → $90 | Reiterates | → Buy | |||
02/28/2023 | 100.91% | Guggenheim | → $53 | Reiterates | → Buy | |||
02/28/2023 | 108.49% | Credit Suisse | $51 → $55 | Maintains | Outperform | |||
02/28/2023 | 127.45% | Chardan Capital | → $60 | Reiterates | → Buy | |||
11/23/2022 | 59.21% | UBS | $40 → $42 | Maintains | Buy | |||
11/23/2022 | 116.07% | Goldman Sachs | $47 → $57 | Maintains | Buy |
Le dernier objectif de prix pour uniQure (NASDAQ:QURE) a été rapporté par Goldman Sachs le novembre 4, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $38.00 s'attendant à ce que QURE se rise dans les 12 prochains mois (un possible changement de 44.05% upside). 41 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
La dernière note d'analyste pour uniQure (NASDAQ:QURE) a été fournie par Goldman Sachs, et uniQure maintenu leur note neutral.
La dernière amélioration pour uniQure NV a eu lieu le décembre 10, 2024 lorsque Raymond James a augmenté leur objectif de prix à $52. Raymond James avait précédemment an outperform pour uniQure NV.
La dernière réduction pour uniQure NV a eu lieu le novembre 4, 2025 lorsque William Blair a changé leur objectif de prix de N/A à N/A pour uniQure NV.
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de uniQure, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour uniQure a été déposée le novembre 4, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 4, 2026.
Bien que les évaluations soient subjectives et changeront, la dernière note de uniQure (QURE) était un maintenu avec un objectif de prix de $56.00 à $38.00. Le prix actuel de uniQure (QURE) est de $26.38, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.